Paclitaxel-coated devices not linked to death risk in PAD patients: NEJM

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-02-06 06:15 GMT | Update On 2021-02-06 07:03 GMT

Sweden: The use of paclitaxel-coated devices versus uncoated endovascular devices is not associated with a significant increase in mortality risk, reveals results from an unplanned interim analysis of the SWEDEPAD trial. The findings were published in the New England Journal of Medicine.

The results from the analysis puts to rest concerns aroused from findings of a recent meta-analysis that showed an increased risk of death with the use of paclitaxel-coated angioplasty balloons and stents in lower-limb endovascular interventions for symptomatic peripheral artery disease.

Mårten Falkenberg, Gothenburg University, Gothenburg, Sweden, and colleagues conducted an unplanned interim analysis of data from SWEDEPAD -- a multicenter, randomized, open-label, registry-based clinical trial. At the time of analysis, 2289 patients were assigned to treatment with drug-coated devices (the drug-coated–device group, 1149 patients) or treatment with uncoated devices (the uncoated-device group, 1140 patients).

Randomization was stratified according to the severity of the disease based on whether patients had chronic limb-threatening ischemia (1480 patients) or intermittent claudication (809 patients). The single end point for this interim analysis was all-cause mortality.

No patients were lost to follow-up. Paclitaxel was used as the coating agent for all the drug-coated devices.

Key findings of the study include:

During a mean follow-up of 2.49 years, 574 patients died, including 293 patients (25.5%) in the drug-coated–device group and 281 patients (24.6%) in the uncoated-device group (hazard ratio, 1.06).
At 1 year, all-cause mortality was 10.2% (117 patients) in the drug-coated–device group and 9.9% (113 patients) in the uncoated-device group.
During the entire follow-up period, there was no significant difference in the incidence of death between the treatment groups among patients with chronic limb-threatening ischemia (33.4% [249 patients] in the drug-coated–device group and 33.1% [243 patients] in the uncoated-device group) or among those with intermittent claudication (10.9% [44 patients] and 9.4% [38 patients], respectively).

"In this randomized trial in which patients with peripheral artery disease received treatment with paclitaxel-coated or uncoated endovascular devices, the results of an unplanned interim analysis of all-cause mortality did not show a difference between the groups in the incidence of death during 1 to 4 years of follow-up," wrote the authors.

The study titled, "Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease," is published in the New England Journal of Medicine.

DOI: https://www.nejm.org/doi/full/10.1056/NEJMoa2005206

Article Source : New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Paclitaxel-coated devices not linked to death risk in PAD patients: NEJM

Similar News

Catheter Ablation Beats Drug Therapy in Atrial Fibrillation Patients With Lower Risk Factors: CABANA Subanalysis

Handheld Ultrasound Proves Effective for VExUS Assessment in Critically Ill Patients: Study

New study reveals Gender-Based Differences in Diabetes Outcomes

Asthma Tied to Higher Risk of Heart Valve Disease, BMJ Study Finds

Stress Hyperglycemia Ratio and Hypertension Closely Associated with Stroke Risk: Study

Intermittent Fasting Under 8 Hours May Raise Heart Death Risk by 135 Percent: Study Finds

Evolocumab Plus Statins Shows Significant Intracranial Plaque Regression Compared to Statins Alone: Study

Chinese Herbal Foot-Baths Show Promise for Early-Stage Diabetic Foot Care: Study